AveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference
June 06 2016 - 5:00PM
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company
developing novel treatments for patients suffering from rare and
life-threatening neurological genetic diseases, today announced
that members of the management team will present at two upcoming
investor conferences:
- The Goldman Sachs 37th Annual Global Healthcare Conference at
10:00 a.m. PDT (1:00 p.m. EDT), Wednesday, June 8, 2016 in Rancho
Palos Verdes, Calif.
- The Jefferies 2016 Healthcare Conference at 12:30 p.m. EDT,
Friday, June 10, 2016 in New York City
Live, listen-only webcasts of the presentations will be
accessible on the Events and Presentations page within the
Investors and Media section of the AveXis website at
www.AveXis.com. A replay of each presentation will be
available at the same location for 30 days following each
conference.
About SMASMA is a severe neuromuscular disease
characterized by the loss of motor neurons leading to progressive
muscle weakness and paralysis. SMA is caused by a genetic defect in
the SMN1 gene that codes SMN, a protein necessary for survival of
motor neurons. The incidence of SMA is approximately one in 10,000
live births.
The most severe form of SMA is Type 1, a lethal genetic disorder
characterized by motor neuron loss and associated muscle
deterioration, which results in mortality or the need for permanent
ventilation support before the age of two for greater than 90
percent of patients. SMA Type 1 is the leading genetic cause of
infant mortality.
About AVXS-101 AVXS-101 is a proprietary gene
therapy candidate of a one-time treatment for SMA Type 1 and is the
only clinical-stage gene therapy in development for SMA. AVXS-101
is designed to address the monogenetic root cause of SMA and
prevent further muscle degeneration by addressing the defective
and/or loss of the primary SMN gene. AVXS-101 also targets motor
neurons providing rapid onset of effect, and crosses the blood
brain barrier allowing an IV dosing route and effective targeting
of both central and systemic features.
About AveXis, Inc. AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in an ongoing Phase 1 clinical trial for the treatment of SMA Type
1. For additional information, please visit www.avexis.com.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024